Benzinga · Jul 30, 2026
Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75
Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and raises the price target from $60 to $75.
QU
NASDAQ · QURE
uniQure N.V.
Healthcare · Biotechnology
$48.37
Down-$0.52 (-1.06%)
Updated Aug 22, 2026, 2:43 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.07B
- P/E ratio
- -4.92
- Dividend yield
- 0.00%
- 52-week range
- $13.21 – $50.47
- Volume
- 673.86K
- Avg. volume
- 4.73M
Price performance
QURE price history
1M range · 21 trading sessions · Daily adjusted prices
QURE closed at $48.37 after 21 trading sessions, up 24.12% for the selected period.
- Last close
- $48.37
- Period change
- +24.12%
- Period low
- $36.66
- Period high
- $48.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $48.91 | $49.845 | $48.19 | $48.37 | 673.86K |
| Aug 20, 2026 | $48.00 | $49.64 | $47.08 | $48.89 | 1.2M |
| Aug 19, 2026 | $48.00 | $49.015 | $46.93 | $48.76 | 1.28M |
| Aug 18, 2026 | $47.42 | $48.20 | $46.8701 | $47.38 | 501.34K |
| Aug 17, 2026 | $48.08 | $48.4999 | $46.87 | $47.97 | 838.63K |
| Aug 14, 2026 | $47.06 | $48.70 | $46.31 | $48.62 | 957.69K |
| Aug 13, 2026 | $44.96 | $47.27 | $44.22 | $47.06 | 1.13M |
| Aug 12, 2026 | $45.11 | $46.1509 | $44.93 | $45.13 | 737.52K |
| Aug 11, 2026 | $46.01 | $46.50 | $44.64 | $45.00 | 984.43K |
| Aug 10, 2026 | $46.06 | $47.00 | $45.1237 | $46.06 | 1.1M |
| Aug 7, 2026 | $46.59 | $48.105 | $45.02 | $46.42 | 1.83M |
| Aug 6, 2026 | $44.15 | $45.48 | $43.90 | $45.36 | 1.27M |
| Aug 5, 2026 | $43.90 | $44.5099 | $43.22 | $44.24 | 799.95K |
| Aug 4, 2026 | $44.21 | $44.73 | $42.56 | $43.68 | 1.29M |
| Aug 3, 2026 | $43.67 | $44.755 | $42.22 | $44.06 | 1.06M |
| Jul 31, 2026 | $43.65 | $44.99 | $43.00 | $43.63 | 1.7M |
| Jul 30, 2026 | $41.69 | $42.5573 | $39.92 | $42.19 | 1.96M |
| Jul 29, 2026 | $38.00 | $42.00 | $37.4317 | $40.07 | 3.86M |
| Jul 28, 2026 | $37.59 | $38.015 | $35.34 | $36.66 | 3.01M |
| Jul 27, 2026 | $38.50 | $40.00 | $38.16 | $38.21 | 1.48M |
| Jul 24, 2026 | $39.30 | $39.44 | $37.33 | $38.97 | 1.35M |
Latest QURE news
The latest Smart Investors Daily articles mentioning QURE.
Stock researchCompany · Overview
QURE research
Overview
Company profile and research snapshot.
Company profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $55.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 30, 2026 | Wolfe Research | Outperform | — |
| Jul 30, 2026 | Barclays | Overweight | — |
| Jun 29, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 25, 2026 | Mizuho | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 30, 2026
Wolfe Research Upgrades uniQure to Outperform, Announces $65 Price Target
Wolfe Research analyst Rudy Li upgrades uniQure (NASDAQ:QURE) from Peer Perform to Outperform and announces $65 price target.
Benzinga · Jul 30, 2026
Barclays Maintains Overweight on uniQure, Lowers Price Target to $60
Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the price target from $65 to $60.
SeekingAlpha · Jul 29, 2026
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
uniQure N.V. (QURE) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsChiara Russo - Senior Director of Investor RelationsMatthew Kapusta -...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
